UpDoc's agent clears the FDA 🩺, Trase banks $107M 🏦, Your inbox becomes the clinic 📨
UpDoc gets the first FDA clearance for an agentic clinical AI — and a $18M seed to go with it
UpDoc, founded by Stanford Medicine researchers, announced FDA clearance on June 25 for what it calls the first agentic clinical AI platform — agents that adjust medications, order labs, and coordinate care between scheduled visits.
It came with an oversubscribed $18M seed (Eli Lilly, Mayo Clinic, the American Diabetes Association, Section 32, Pear, Polaris) and live deployments at Cleveland Clinic, Allegheny Health Network, and UCSF.
Here’s the part the press release glides past: the underlying clearance looks narrow — a 510(k) scoped to automated insulin dosing, riding the d-Nav predicate — while the WSJ framing paints a sweeping “concierge doctor between visits.”
The agent that adjusts the dose got cleared. The clinician whose name is on the order still owns what happens next.
This is the year AI crosses from reads-and-flags to talks-and-acts — and the accountability layer didn’t move with it. For builders, the lesson isn’t the funding round. It’s that the regulatory pathway is now a product decision: UpDoc went the federal SaMD route; Doctronic is being regulated at the state level as the practice of medicine. Same capability, opposite moats.
😤 “This is an insulin-dosing algorithm with a press release.” Partly, yeah — and that’s exactly the tell. The clearance is narrow; the vision is broad. The gap between what cleared and what’s marketed is where every regulated-AI builder actually lives. Naming that gap honestly is the skill.
😤 “FDA clearance means it’s safe.” Clearance means it matched a predicate. Safety is present-tense; clearance is past-tense.
😤 “Doctors will never let an AI change a dose.” They already let order sets, protocols, and pharmacy algorithms change doses every day. The question was never whether — it’s who signs when it’s wrong.
❓ What’s the product that lives between UpDoc’s federal SaMD route and Doctronic’s state practice-of-medicine route?
Trase raises a $107M seed to be the operating system for AI agents in regulated industries
Trase closed an unusually large $107M seed (ARCH Venture Partners, Red Cell) for an agent OS aimed at healthcare and other high-stakes fields, with a live Duke Heart Center deployment.
The thesis investors are now paying for: in regulated work, the moat isn’t the model — it’s the governance, audit trail, and predictability around the agent.
The capital is moving toward the boring layer — the part that makes an agent’s actions defensible, not just impressive.
😤 “$107M for a seed? That’s a vibes round.” Maybe. But notice what got funded: not a clinical model, the connective tissue around agents acting safely. That’s a bet that the action layer, not the intelligence layer, is where the durable value sits.
💡 80/20: Whatever you build with agents, build the receipt first — who acted, on what authority, with what inputs, reversible how.
Patient messages now outpace office visits — and that’s a demand signal, not a burden
A JAMA study of 140M+ records across 2,067 hospitals found patient-authored portal messages surged 153% from 2020 to 2025 — now outpacing in-person visits, with messaging expanding between-visit care rather than replacing it.
The reflex is to treat the inbox as a problem to absorb: more staff, more after-hours clicks, bill for messages. The sharper read is that the volume is unmet demand to be heard — people reaching for the closest thing to an inside line.
The message isn’t the problem. It’s the signal that the visit-shaped system no longer fits how people actually seek care.
😤 “So we should just let AI auto-reply to patients?” No — auto-replying to a demand signal is how you turn a person who finally reached out into a person who never will again. The build is triage and routing that gets the scary message to a human faster, not a bot that closes the loop on the cheap.
❓ The patient is the only actor in this system without an AI working for them — the clinician has scribes, the payer has denial engines, the patient has a portal they can barely log into. What does the patient’s agent look like, and who’s allowed to build it?
Hera raises $27M for chronic-care management on Original Medicare
Hera raised $27M for a CCM platform staffing 1099 RNs and social workers who bill “incident to” a physician to coordinate care for fee-for-service Medicare patients with 2+ chronic conditions — reportedly at ~60% gross margins.
The between-visit gap isn’t just a clinical problem — it’s a reimbursable business with real unit economics, and the codes already exist.
💡 80/20: If you’re building between-visit tooling, the CCM/RPM/APCM code stack is the revenue rail that’s already there. Learn which actions map to which codes before you build the workflow — the billing logic is the product spec.
Quick hits
Chris Klomp nominated as Deputy HHS Secretary. The CMS Medicare Director was nominated as #2 at HHS — a health-tech-literate operator now over operations and regulatory policy. Worth watching for anyone whose roadmap touches Medicare Advantage or interoperability rulemaking.
Epic / UCHealth — a behavioral-health unit with no bedside phones gave nurses a MyChart-integrated meal-ordering app instead of routing calls through the kitchen; 99% of meal orders now flow through it. Clean example of workflow redesign that removes burden without adding staff.
Angel Arnaout, MD (Healthcare Management Forum) — a sharp paper arguing AI capability is an organizational property (infrastructure, governance, skill, culture), not a purchase; route AI requests through problem statements, not technology requests. The “AI-capable organization” framing is the buyer-side mirror of today’s Big Thing.
🛠️ From the Workbench
Connecting WHOOP to Claude — Christian Pean MD wrote a hands-on guide for piping WHOOP recovery, sleep, and strain data into Claude so a scheduled task files your nightly metrics into a folder and a living dashboard. About 15 minutes of setup (WHOOP membership, a WHOOP developer account, Node.js), with a no-code export shortcut for the less technical. The real lesson isn’t the wearable — it’s the pattern: a scheduled agent turning a stream of “data I have” into “data I can think with.”
⚠️ Verify: this is your own consumer data on your own machine — fine for a personal longevity log. The moment you point this pattern at patients, you’ve left wellness data and entered PHI, and the WHOOP developer terms and your health system’s data rules both apply.
💡 80/20: Build the pattern on your own wearable data this weekend, then ask what it teaches you about the clinical version: what would a between-visit “how am I trending?” agent need, and what’s the first thing that would break when the data is someone else’s?
🎙️ From the Pods
🎙️ HIMSSCast — “Full-body scans for longevity” (with BodySpec CEO Elaine Shi)
DEXA body-composition scans surface visceral fat and lean mass that the scale and BMI hide — and Shi notes clients increasingly pull their DEXA results “into their LLM of choice” to reason about long-term risk, not just today’s number.
💡 Builder take: The wearable-and-scan → LLM workflow is becoming the default consumer move. The opportunity isn’t the measurement; it’s the trustworthy layer that turns longitudinal body data into a decision a clinician would actually endorse.
🔇 Speaker Blindspot: Selection bias — the people who scan monthly are the already-converted quantified-self crowd. The patients who’d benefit most from catching visceral fat early are exactly the ones who’ll never book a voluntary DEXA, and the episode treats the engaged self-tracker as the norm.
“I always want to be confronted with the truth.” — Elaine Shi
🎙️ HLTH Webinar — “Unlocking Innovation with Rural Health Transformation”
The federal Rural Health Transformation Program will push $50B to states over five years — for scale, that’s roughly HiTECH’s ~$29B but in half the time, with ~$200M per state in year one. The panel’s repeated warning: this only works if the money buys sustainable operating models, not one-off projects.
💡 Builder take: A lot of that money will land on rural AI and automation to stretch scarce clinical staff. If you build for low-resource settings, the move is to engage state health leaders now — the year-two applications are where real innovation gets funded.
🔇 Speaker Blindspot: Appeal to scale — the panel leans on the size of the check as if $50B plus technology automatically modernizes rural care. They name DSRIP as a cautionary tale but don’t reckon with why those grants funded projects that evaporated when the dollars did. Bigger pile, same failure mode unless the operating-model discipline is real.
📅 This Week in Health AI Events
Free virtual events for clinician-builders — attend live or catch the recording later.
Tue Jun 30 — Clinician in the Loop: AI Investment to Real-World Impact (CHIME, LinkedIn Live)
12:00 PM ET · LinkedIn Live · Free · Replay available
For CMIOs and clinical leaders: how to tell whether your AI is actually working post-deployment, and the gap between vendor promises and clinical reality. The 30-minute format makes it an easy lunch watch.
Tue Jul 14 — Becker’s Oncology Virtual Event (Becker’s Healthcare)
1:00 PM CST · Virtual · Free to register · Sessions archived
A close look at how AI lands in a high-stakes specialty — where the tolerance for error is lowest and the workflow questions are hardest.
Thu Jul 16 — Accountability in Practice: Responsible AI Use in Healthcare (AHIP / URAC)
1:00 PM ET · Virtual · Free
Bias, transparency, and oversight from the payer’s seat — plus how a standards-based framework keeps an AI deployment defensible.
Tue Jul 21 — Becker’s AI + Digital Health Virtual Event (Becker’s Healthcare)
1:00 PM CST · Virtual · Free to register · Sessions archived
The most on-topic event on the calendar — a full half-day on AI and digital health in care delivery. Worth registering now even though it’s a few weeks out.
💡 BTW: Grant Verstandig, who just raised $107M for Trase, founded his first health company — Rally Health (originally Audax) — after dropping out of Brown at 21, having endured seven-plus knee surgeries including a meniscus transplant. He and his surgeon disagreed about what “a good outcome” even meant, and that argument sent him into building. Fortune
What are you building this week? Email and tell me (kevin@clinicians.build) — I read every one.
— Kevin